Medicinal treatments of cholesterol gallstones: old, current and new perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review with mechanism-based reasoning and no primary data or systematic search methodology
PubMed 19355905 · doi:10.2174/092986709787909631
What was done
This narrative review summarizes medical management strategies for cholesterol gallstone disease, focusing on patient selection criteria for oral litholysis with ursodeoxycholic acid and reviewing experimental mechanisms involving intestinal cholesterol absorption inhibition (ezetimibe via NPC1L1) and nuclear receptor modulation.
What was found
The abstract reports no quantitative data or numerical outcomes. It describes that non-surgical therapy is restricted to a small subset of patients with mild symptoms and small, radiolucent, cholesterol-enriched stones inside a functioning gallbladder with a patent cystic duct. It notes that ursodeoxycholic acid acts by desaturating biliary cholesterol and that ezetimibe and nuclear receptor modulators demonstrate potential in preclinical models and preliminary human studies.
Why it matters
It outlines the narrow clinical indications where non-surgical management remains an alternative to cholecystectomy and highlights emerging molecular targets for pharmacological prevention and treatment of cholesterol gallstones.
Limits
As a narrative review, it lacks a systematic search strategy, quality appraisal of included studies, and quantitative synthesis. The abstract provides no primary human trial data, sample sizes, or precise therapeutic efficacy rates.
Cited by
- supports Gallstones can be dissolved using bile salts.